Vivjoa®

Drug - Vivjoa® (oteseconazole) [Mycovia Pharmaceuticals, Inc.]

March 2025

Therapeutic Area - Antifungals, Oral

Approval criteria

Patient has diagnosis of recurrent vulvovaginal candidiasis with three or more episodes of vulvovaginal candidiasis (VVC) in a 12-month period; AND
Patient is a biological female who is postmenopausal or has another reason for permanent infertility (e.g., tubal ligation, hysterectomy, salpingo-oophorectomy); AND
Patient must not have hypersensitivity to any component of the product; AND
Patient is not pregnant; AND
Patient is not lactating; AND
Patient has tried and failed or has a contraindication or intolerance to maintenance antifungal therapy with weekly oral fluconazole for 6 months.

Provider Call Center (844) 575-7887